* Exagen Inc XGN.OQ XGN.O is expected to show a fall in
quarterly revenue when it reports results on March 20.
* The Vista California-based company is expected to report
a
31.8% decrease in revenue to $8.657 million from $12.69 million
a year ago, according to the mean estimate from 6 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Exagen Inc is for a
loss
of 78 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Exagen Inc
is
$6.5, above its last closing price of $2.36.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.73 -0.73 -0.47 Beat 35.6
Jun. 30 2022 -0.57 -0.57 -0.78 Missed -36.8
Mar. 31 2022 -0.61 -0.61 -0.60 Beat 1.4
Dec. 31 2021 -0.44 -0.50 -0.42 Beat 15.4
Sep. -0.47 -0.46 -0.42 Beat 8.7
30 2021
Jun. 30 2021 -0.47 -0.44 -0.38 Beat 13
Mar. 31 2021 -0.47 -0.47 -0.48 Missed -2.3
Dec. 31 2020 -0.38 -0.41 -0.27 Beat 33.4
This summary was machine generated March 17 at 20:42 GMT. All
figures in US dollars unless otherwise stated